Navigation Links
Science Translational Medicine: 'Creating Hope Act' incentivizes pediatric drug R&D
Date:1/19/2011

Washington, DC Recent legislative and regulatory actions make great strides toward establishing much needed incentives for pharmaceutical companies and others to develop and test more medications for pediatric rare diseases, including pediatric cancers, according to commentary by experts from Children's National Medical Center. The commentary appears in the January 19 issue of Science Translational Medicine.

"Pediatricians who treat children with serious and life-threatening diseases often find themselves face to face with the inadequacies of pediatric drug development," write Edward Connor, MD, director of the Office of Innovation Development and Investigational Therapeutics at Children's National Medical Center, and Pablo Cure, MD, MPH, Laboratory for Entrepreneurial Achievement in Pediatrics (LEAP) Scholar in the Office of Innovation Development and Investigational Therapeutics.

In a previous commentary for this journal, Dr. Connor noted that despite the fact that children make up nearly 40 percent of the world's population, little research is done to test the effects of "adult therapies" on children, who have unique needs requiring tailored care more sophisticated than merely smaller doses of adult therapeutics. The demand for pediatric drugs, especially those for rare diseases like childhood cancer, is relatively low compared to the demand for adult drugs, as fewer children develop rare and serious illnesses. To maximize efficacy and return on investment, pharmaceutical developers sometimes focus their efforts on therapeutics that address illnesses common to larger populations.

Pediatric specialists frequently have to prescribe therapeutics for children "off-label" because many common drugs and devices for treating diseases are only tested in adults but are necessary for the treatment of children. Research, however, has shown repeatedly that drugs and devices for adults can impact children differently.

According to the authors, the Creating Hope Act of 2010 that is pending before Congress recognizes the importance of stimulating pediatric drug development. It updates the existing Priority Voucher for Neglected Diseases Program to include rare and serious diseases of childhood. That program offers a financial incentive to companies developing drugs for neglected diseases.

"Although government support is critical," the authors continued, "it is not sufficient to produce productsfor use in children. Incentive programs like the Creating Hope Act and other approaches designed to motivate drug development for children are also needed. Our investment in biomedical research is providing returns, and we need to assure that children, the most vulnerable among us, benefit from this investment as well."


'/>"/>

Contact: Jennifer Stinebiser
jstinebi@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related medicine news :

1. Dartmouth Medical School faculty named fellows of the American Association for the Advancement of Science
2. New Society for Social Neuroscience to help guide emerging field
3. fMRI special section of Perspectives on Psychological Science
4. Fresh Seafood Shouldnt Smell Fishy, Food Science Expert Says
5. Dr. Oliver Daumke of MDC wins Bayer Early Excellence in Science Award
6. Professor John Shine wins 2010 Prime Ministers Prize for Science
7. Four NYU researchers receive New York Academy of Sciences 2010 Young Scientists awards
8. Saturday news tips: Resuscitation Science Symposium
9. Yerkes researchers present at 40th Annual Society for Neuroscience Conference
10. Academies of science call for amendments to impracticable Genetic Diagnostics Act
11. Louisiana State University Health Sciences Center research shows fish oil component given up to 5 hours after stroke limits brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 24, 2017 , ... Element Blue ™, a leading ... strategic partnership with Lucidworks , the company transforming the way people access ... for building powerful enterprise search applications. , Element Blue is a global team ...
(Date:1/24/2017)... ... January 24, 2017 , ... i2i Population Health, a national leader ... , “Cary’s broad financial background is an excellent fit for i2i,” ... and day-to-day financial operations skills we need to take the company to the next ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... The ... MSC Cruises as part of the line’s 4th Annual MSC True Partnerships’ Awards. ... performing North American travel partners for the year based on overall business growth in ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups ... of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and ... The entrepreneurs will showcase their businesses on February 6, 2017, at Under Armour’s ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health ... annual Solutions Series of webinars will start January 31 with a session about ... of current health and benefits topics, including employee engagement, pricing transparency, population health ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... India , Jan. 24, 2017 Market Research Future has ... Market for Wound Closure Device is growing rapidly and expected to continue ... ... at a CAGR of 5% from 2013 to 2019 and reaching a ... of the forecasted period, 2016-2022 Global Wound Closure Device Market ...
(Date:1/24/2017)... Nev. , Jan. 24, 2017  The ... that specializes in high-value orthopaedic implants, announced the ... today. The OIC Tibial Nail ... tibia. Strategically placed proximal and distal screw holes ... hole that allows dynamization.  The nail is available ...
(Date:1/24/2017)... 2017 Trifecta Clinical , a leading ... Rick Ward to Vice President of Commercial ... also announcing the promotion of Ericka Atkinson ... Rick joins Trifecta from Greenphire where he was ... business development positions within the healthcare industry throughout his ...
Breaking Medicine Technology: